Table 6.
Secondary outcome measures (IRQ, GOS-E, EQ-5D-5L, SF-12, HADS)
| Outcome | Time point | Placebo | Risperidone |
| N mean±SD | N mean±SD | ||
| IRQ patient | Baseline* | 7 34±6 | 5 37±19 |
| Severity | Week 12 | 7 26±7 | 5 25±14 |
| Change† | 7–8±9 | 5–13±13 | |
| IRQ carer | Baseline* | 5 10±4 | 5 14±5 |
| Severity | Week 12 | 5 7±4 | 5 7±4 |
| Change† | 3–3±2 | 5–6±2 | |
| GOS-E | Baseline* | 7 6.4±1.1 | 5 6.6±1.5 |
| Week 12 | 7 6.4±1.1 | 5 6.8±1.6 | |
| Change† | 7 0.0±0.0 | 5 0.2±0.5 | |
| EQ VAS | Baseline* | 7 53±24 | 5 61±10 |
| Week 12 | 7 57±30 | 5 64±21 | |
| Change† | 7 4±11 | 5 3±18 | |
| SF-12 | Baseline* | 7 44±13 | 5 51±10 |
| Physical | Week 12 | 7 43±11 | 5 47±12 |
| Change† | 7 0±14 | 5–3±5 | |
| SF-12 | Baseline* | 7 34±14 | 5 30±12 |
| Mental | Week 12 | 7 41±15 | 5 40±19 |
| Change† | 7 7±18 | 5 9±13 | |
| HADS anxiety | Baseline* | 7 8.6±3.8 | 5 9.6±6.9 |
| Week 12 | 7 6.7±3.8 | 5 6.8±7.2 | |
| Change† | 7–1.9±3.5 | 5–2.8±1.8 | |
| HADS depression | Baseline* | 7 9.9±5.5 | 5 4.8±4.2 |
| Week 12 | 7 7.9±4.7 | 5 5.0±3.9 | |
| Change† | 7–2.0±2.8 | 5 0.2±2.9 |
*Summary statistics only for patients with values at 12 weeks.
†Calculated as value at week 12 minus value at baseline.
GOS-E, Glasgow Outcome Scale-Extended; HADS, Hospital Anxiety and Depression Scale; IRQ, Irritability Questionnaire.